Regulatory Agency Administrative Shutdown and Final Approval Timeline

The EMA (European Medicines Agency) will officially suspend all administrative operations from 6:00 PM on April 1, 2026, to 8:30 AM on April 7, 2026, due to the Easter holiday. During this period, the submission of official documents and system processing will be limited, which will inevitably cause a short-term bottleneck in the regulatory review timeline for bio-companies preparing to enter the European market. In particular, regulatory approvals are a sensitive area where even a one-day difference can affect the timing of commercialization and the inflow of partnership milestones, so careful schedule management is needed to address the administrative gap.

Impact on Market Launch of Drugs Recommended by the CHMP in March

This holiday will directly affect the final approval process for new drugs that received a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) meeting held from March 23 to 26, 2026. Representative examples include Imdylltra (ingredient name: tarlatamab), a bispecific antibody targeting DLL3 for small cell lung cancer (SCLC) from Amgen, and Joenja (ingredient name: leniolisib), an APDS treatment from Pharming Group. Typically, it takes about 67 days from the CHMP recommendation to the final marketing authorization approval by the European Commission (EC), but there is a possibility that the commercial launch timeline may be slightly delayed due to the one-week administrative shutdown.

Increased Risk of Responding to Outstanding Issues for Companies Awaiting CHMP Review in April

Companies preparing to submit additional data or answer questions (List of Outstanding Issues) in preparation for the April CHMP meeting scheduled from April 20 to 23, 2026, may face increased risks in responding. This is because they will be cut off from receiving feedback from regulatory authorities or communicating closely with reviewers, making it difficult to respond quickly to unexpected events. If the submission of essential documents is delayed during this period, the announcement of the review results may be postponed to the May meeting, leading to a serious regulatory delay of more than one month in the development schedule.

Impact of European Regulatory Risks on Global Biotech

Europe is a key hub, second only to the U.S. FDA, in the global pharmaceutical market, and changes in the schedules of regulatory agencies can affect corporate value. In particular, the small cell lung cancer market is expected to grow to approximately USD 5.5 billion by 2030, making it a key battleground. This is a significant event not only for large pharmaceutical companies such as Amgen but also for small and medium-sized biotech companies that have signed license-out agreements. Investors should not simply dismiss this as a holiday schedule but should analyze the timing of regulatory milestones for pending pipelines and the resulting short-term cash flow of the company in a multifaceted way to prepare for risks in advance.